George Georges, MD

George Georges, MD

Associate Member
Clinical Research Division
Associate Professor of Medicine
University of Washington


Massachusetts Institute of Technology, 1986, BS
University of California, San Francisco, 1990, MD

Research Focus:

  • Hematopoietic cell transplantation for severe autoimmune diseases: Autologous and allogeneic transplantation for diseases including systemic sclerosis, multiple sclerosis and aplastic anemia.
  • Nonmyeloablative hematopoietic cell transplantation: Regimens to reduce the toxicity of allogeneic transplantation, particularly in older patients or patients with medical comorbidities.
  • Hematopoietic stem cell and T cell gene therapy: Laboratory-based studies on hematopoietic stem cell expansion and genetic correction of underlying disease.
  • Development of radiation mitigators, for example, to reduce toxicity of gastrointestinal syndrome after irradiation.

Clinical Expertise:

  • Hematopoietic cell transplantation for hematologic malignancies (leukemia, lymphoma and other malignancies) and autoimmune diseases (systemic sclerosis, multiple sclerosis and aplastic anemia).
  • Treatment of acute and chronic graft-versus-host disease.
  • Nonmyeloablative conditioning regimens for allogeneic hematopoietic cell transplantation

Current Studies:

  • Protocol 2260 High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases
  • Protocol 2533 A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis
  • Protocol 2067 Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis
  • Protocol 1990 The Effect of Allogeneic Hematopoietic Cell Transplantation on the Activity and Progression of Multiple Sclerosis
  • Protocol 1581 Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia – a Multi-Center Trial
  • Protocol 1948 A Randomized, Open-Label, Phase II/III Multi-Center Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation with Auto-CD34+HPC versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis
  • Protocol 1997 A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosis
  • “Increasing Stem Cell Numbers While Retaining Stem Cell Function” Ancillary/Collaborative Studies for the NHLBI Progenitor Cell Biology Consortium. Laboratory based project involving ex vivo expansion of CD34+ progenitor cells and gene marking.
  • “Beclomethasone post-exposure therapy for gastrointestinal acute radiation syndrome” NIAID R43 AI100417

George Geroges, MD

Contact Information

(206) 667-6886
(206) 667-6124
Additional contact

Mail Stop: D1-100